Advertisement

Decomposing Out-of-Pocket Health Spending: Share of Drugs, Medical Services and Other Components

  • Moneer Alam
Chapter
Part of the India Studies in Business and Economics book series (ISBE)

Abstract

The preceding discussion has perhaps clearly underscored the fact that ailments and poor health conditions contribute heavily in exposing households to serious economic issues, press them hard to make OOP expenses, push a number of them to slip below the threshold poverty level (see the last two columns in Appendix Table 6.A.1) and render many to meet with serious catastrophic situations—amounting to curtailments in their normal consumption pattern and forcing them in certain cases to borrow from private moneylenders. All these make analysts to ask an obvious question: Why is there so much of OOP health spending, and what and where public policy interventions could be directed to ameliorate the situation? In certain countries, the answer to these questions rests with demographically mediated age structure changes and rapid population ageing (Dormont and Huber 2006; Dormont et al. 2006; Getzen 1992). Given the fact that in many cases health-care expenses are determined by the progressing age of the older adults, the growing share of 60 or 65+ is expected to increase the size of health expenditure both in a society and in a household. With ageing in India yet to reach the level achieved by many developed countries, a great deal of health expenditure in this or similar other countries may not be simply considered as age-driven or caused by the ailing olds. Components of health care, in particular, high costs of medicinal drugs and diagnostics, may as well play a role and make families incur a much greater spending on health. This has also been argued by the studies conducted on the initiative of the government including NCMH (2005, Sec. II) or the Annual Report to the People on Health (Ministry of Health & Family Welfare, Government of India, December 2011, Chapter VII).

Keywords

Health Expenditure Health Budget Compulsory Licence Budget Share Quintile Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Bonu, S., Indu, B., & Peters, David H. (2007, October). Incidence, intensity and correlates of catastrophic OOP health payment in India (ERD Working Paper No. 102). Malina: Asian Development Bank.Google Scholar
  2. Chaudhury, S. (2005). The WTO and India’s pharmaceutical industry – Patent protection, TRIPS and developing countries. New Delhi: Oxford University Press.Google Scholar
  3. Cullet, P. (2005). Intellectual property protection and sustainable development. New Delhi: Lexis Nexis Butterworths.Google Scholar
  4. Dormont, B., & Huber H. (2006, July–December). The predominance of changes in medical practices over population ageing. Annales d’ Économie et de Statis, 83/84, Health, Insurance, Equity, 187–217. http://www.Jstor.org/stable/20079168. Accessed Apr 2009.
  5. Dormont, B., Grignon, M., & Huber, H. (2006). Health expenditure growth: Reassessing the threat of ageing. Health Economics, 15, 947–967.CrossRefGoogle Scholar
  6. Getzen, T. E. (1992). Population ageing and the growth of health care expenditures. Journal of Gerontology, 47, S98–S104.CrossRefGoogle Scholar
  7. Kamiike, A., & Sato, T. (2011). The TRIPs agreement and pharmaceutical industry: The Indian experience. Paper presented in the conference on comparative aspects on culture and religion: India, Russia, China’, SRC and CSCS, Bangalore. http://src-h.slav.hokudai.ac.jp/rp/group_06/activities/files/20110915_16/20110916_KamiikeSato.pdf Accessed in Feb.
  8. Lalitha, N. (2011). Access to Indian generic drugs: Emerging issues. In K. C. Shadlen, S. Guennif, A. Guzman, & N. Lalitha (Eds.), Intellectual property, pharmaceuticals and public health: Access to drugs in developing countries (pp. 225–252). Cheltenham/Northampton: Edward Elgar.Google Scholar
  9. Narayan, S. (2007, March 19). Price control on pharmaceutical products in India (ISAS Working Paper No. 20). Singapore: National University of Singapore: Institute of South Asian Studies (ISAS).Google Scholar
  10. NCMH, MoHFW (Government of India). (2005, August). Report of the National Commission on Macroeconomics and Health, Chapter 2 on India’s health system: The financing and delivery of health care services pp. 15–81.Google Scholar
  11. Rane, W. (1999, June 30). Rise in drug prices since 1987 – An analysis. Economic and Political Weekly, 1375–1379.Google Scholar
  12. Sakthivel, S. (2005, August). Access to essential drugs and medicine. Background paper prepared for the report “Financing and delivery of health care services in India” (pp. 185–212). National Commission on Macroeconomics and Health, Ministry of Health and Family Welfare, Government of India.Google Scholar
  13. Selvaraj, S., & Farooqui, H. H. (2012, November 17). Draft drug price policy 2011: Legitimizing unaffordable medicine prices? Economic and Political Weekly, 47(46), 13–17.Google Scholar
  14. Srinivasan, S. (1999). How many aspirins to the rupee: Runaway drug prices. Economic and Political Weekly, 34.Google Scholar
  15. Watal, J. (2000). Pharmaceutical patents, prices and welfare losses: Policy options for India under the WTO rules agreement. World Competition, Review of Law and Economics, 24, 733–752.Google Scholar

Copyright information

© Springer India 2013

Authors and Affiliations

  • Moneer Alam
    • 1
  1. 1.Institute of Economic GrowthDelhi UniversityDelhiIndia

Personalised recommendations